A Phase II Study of Gemzar, Taxotere, and Xeloda (GTX) for Adjuvant Pancreatic Cancer.
Phase of Trial: Phase II
Latest Information Update: 29 Jun 2016
At a glance
- Drugs Capecitabine (Primary) ; Docetaxel (Primary) ; Gemcitabine (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions
- 28 Oct 2011 Planned end date changed from 1 Dec 2011 to 1 Dec 2014 as reported by ClinicalTrials.gov.
- 29 Apr 2009 New trial record